The role of positron emission tomography imaging in understanding Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 4, 2015, Pages 395-406

  Barthel, Henryk ^a   Seibyl, John ^b   Sabri, Osama ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

Alzheimer's disease; amyloid; mild cognitive impairment; nicotine; positron emission tomography; tau

Indexed keywords

AMYLOID BETA PROTEIN; TRACER; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; CHRONOLOGY; DIFFERENTIAL DIAGNOSIS; DRUG SCREENING; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; BRAIN; DRUG EFFECTS; PATHOLOGY; PROCEDURES; SCINTISCANNING;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84925854891     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1023296     Document Type: Review

References (72)

1. Blennow K, de Leon MJ, Zetterberg H.Alzheimer's disease.Lancet 2006; 368(9533): 387-403
2. Alzheimer's Association.Available from: http://www.alz.org
3. Johnson KA, Minoshima S, Bohnen NI, et al.Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.Alzheimers Dement 2013; 9(1): e-1-16
4. Jack CR Jr, Knopman DS, Jagust WJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.Lancet Neurol 2010; 9(1): 119-28
5. Shah M, Catafau AM.Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers.J Nucl Med 2014; 55(6): 871-4
6. Smits R, Fischer S, Hiller A, et al.Synthesis and biological evaluation of both enantiomers of [(18)F]flubatine, promising radiotracers with fast kinetics for the imaging of a4b2-nicotinic acetylcholine receptors.Bioorg Med Chem 2014; 22(2): 804-12
7. Wong DF, Kuwabara H, Kim J, et al.PET imaging of high-Affinity a4b2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics.J Nucl Med 2013; 54(8): 1308-14
8. Hillmer AT, Wooten DW, Slesarev MS, et al.PET imaging of a4b2 nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate.J Nucl Med 2012; 53(9): 1471-80
9. Arthur D, Levin ED.Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response.Psychopharmacology (Berl) 2002; 160(2): 140-5
10. Braak H, Braak E.Neuropathological stageing of Alzheimer-related changes.Acta Neuropathol 1991; 82(4): 239-59
11. Haass C, Selkoe DJ.Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.Nat Rev Mol Cell Biol 2007; 8(2): 101-12
12. Mosconi L, Rinne JO, Tsui WH, et al.Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.Proc Natl Acad Sci USA 2010; 107(13): 5949-54
13. Doré V, Villemagne VL, Bourgeat P, et al.Cross-sectional and longitudinal analysis of the relationship between Ab deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.JAMA Neurol 2013; 70(7): 903-11
14. Lim HK, Nebes R, Snitz B, et al.Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects.Brain 2014; 137(Pt 12): 3327-38
15. Caroli A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.Neurobiol Aging 2010; 31(8): 1263-74
16. Jack CR Jr, Wiste HJ, Weigand SD, et al.Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity.Neurology 2013; 81(20): 1732-40
17. Vos SJ, Xiong C, Visser PJ, et al.Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.Lancet Neurol 2013; 12(10): 957-65
18. Bartus RT, Dean RL 3rd, Beer B, Lippa AS.The cholinergic hypothesis of geriatric memory dysfunction.Science 1982; 217(4558): 408-14
19. Anand P, Singh B.A review on cholinesterase inhibitors for Alzheimer's disease.Arch Pharm Res 2013; 36(4): 375-99
20. Klingner M, Apelt J, Kumar A, et al.Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-Amyloid plaque pathology.Int J Dev Neurosci 2003; 21(7): 357-69
21. Salloway S, Sperling R, Fox NC, et al.Two phase 3 trials of bapineuzumab in mild-To-moderate Alzheimer's disease.N Engl J Med 2014; 370(4): 322-33
22. Villemagne VL, Burnham S, Bourgeat P, et al.Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.Lancet Neurol 2013; 12(4): 357-67
23. LaFerla FM, Hall CK, Ngo L, Jay G.Extracellular deposition of beta-Amyloid upon p53-dependent neuronal cell death in transgenic mice.J Clin Invest 1996; 98(7): 1626-32
24. Kim SH, Suh YH.Neurotoxicity of a carboxyl-Terminal fragment of the Alzheimer's amyloid precursor protein.J Neurochem 1996; 67(3): 1172-82
25. Fripp J, Bourgeat P, Acosta O, et al.Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.Neuroimage 2008; 43(3): 430-9
26. Frisoni GB, Lorenzi M, Caroli A, et al.In vivo mapping of amyloid toxicity in Alzheimer disease.Neurology 2009; 72(17): 1504-11
27. Drzezga A, Grimmer T, Henriksen G, et al.Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.Neurology 2009; 72(17): 1487-94
28. Lim YY, Maruff P, Pietrzak RH, et al.Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.Alzheimers Dement 2014; 10(6): 743-751.e741
29. Jennings D, Seibyl J, Sabbagh M, et al.Age-dependence of brain b-Amyloid deposition in Down syndrome: a [18F] florbetaben PET study.Neurology 2015; 84(5): 500-7
30. Rowe CC, Bourgeat P, Ellis KA, et al.Predicting Alzheimer disease with beta-Amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.Ann Neurol 2013; 74(6): 905-13
31. Barthel H, Gertz HJ, Dresel S, et al.Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.Lancet Neurol 2011; 10(5): 424-35
32. Sabbagh MN, Fleisher A, Chen K, et al.Positron emission tomography and neuropathologic estimates of fibrillar amyloid-b in a patient with Down syndrome and Alzheimer disease.Arch Neurol 2011; 68(11): 1461-6
33. Landt J, D'Abrera JC, Holland AJ, et al.Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar b-Amyloid in adults with down syndrome: safety, acceptability, and feasibility.Arch Neurol 2011; 68(7): 890-6
34. Verny M, Berrut G.Diagnosis of normal pressure hydrocephalus in elderly patients: a review.Geriatr Psychol Neuropsychiatr Vieil 2012; 10(4): 415-25
35. Gareri P, De Fazio P, Manfredi VG, De Sarro G.Use and safety of antipsychotics in behavioral disorders in elderly people with dementia.J Clin Psychopharmacol 2014; 34(1): 109-23
36. Henriksen AL, St Dennis C, Setter SM, Tran JT.Dementia with lewy bodies: therapeutic opportunities and pitfalls.Consult Pharm 2006; 21(7): 563-75
37. Kukull WA, Larson EB, Reifler BV, et al.The validity of 3 clinical diagnostic criteria for Alzheimer's disease.Neurology 1990; 40(9): 1364-9
38. Jellinger K, Danielczyk W, Fischer P, Gabriel E.Clinicopathological analysis of dementia disorders in the elderly.J Neurol Sci 1990; 95(3): 239-58
39. Drzezga A.Amyloid-plaque imaging in early and differential diagnosis of dementia.Ann Nucl Med 2010; 24(2): 55-66
40. Meyer PT, Hellwig S, Amtage F, et al.Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.J Nucl Med 2011; 52(3): 393-400
41. Bohnen NI.2014 SNMMI Highlights Lecture: neuroscience.J Nucl Med 2014; 55: 9N-14N
42. Schroeter ML, Neumann J.Combined imaging markers dissociate Alzheimer's disease and frontotemporal lobar degeneration - An ALE meta-Analysis.Front Aging Neurosci 2011; 3: 10
43. Klein JC, Eggers C, Kalbe E, et al.Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.Neurology 2010; 74(11): 885-92
44. Cummings JL, Doody R, Clark C.Disease-modifying therapies for Alzheimer disease: challenges to early intervention.Neurology 2007; 69(16): 1622-34
45. A4 Study.Available from: http://a4study.org
46. Expedition 3 Study.Available from: https://.www.expedition3study.com
47. Kozauer N, Katz R.Regulation of drugs for early Alzheimer's disease.N Engl J Med 2013; 369(3): 288
48. Kozauer N, Katz R.Regulatory innovation and drug development for early-stage Alzheimer's disease.N Engl J Med 2013; 368(13): 1169-71
49. Lorenzi M, Donohue M, Paternicò D, et al.Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.Neurobiol Aging 2010; 31(8): 1443-51
50. Nordberg A, Lundqvist H, Hartvig P, et al.Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.Dement Geriatr Cogn Disord 1997; 8(2): 78-84
51. Kadir A, Darreh-Shori T, Almkvist O, et al.Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.Psychopharmacology (Berl) 2007; 191(4): 1005-14
52. Kadir A, Darreh-Shori T, Almkvist O, et al.PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-Treated patients with AD.Neurobiol Aging 2008; 29(8): 1204-17
53. Tuszynski MH, Thal L, Pay M, et al.A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.Nat Med 2005; 11(5): 551-5
54. Rinne JO, Brooks DJ, Rossor MN, et al.11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.Lancet Neurol 2010; 9(4): 363-72
55. Kofler J, Lopresti B, Janssen C, et al.Preventive immunization of aged and juvenile non-human primates to b-Amyloid.J Neuroinflammation 2012; 9: 84
56. Landau SM, Lu M, Joshi AD, et al.Comparing positron emission tomography imaging and cerebrospinal fluid measurements of b-Amyloid.Ann Neurol 2013; 74(6): 826-36
57. Zwan M, van Harten A, Ossenkoppele R, et al.Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.J Alzheimers Dis 2014; 41(3): 801-7
58. Brendel M, Hogenauer M, Delker A, et al.Improved longitudinal [F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.Neuroimage 2015; 108: 450-9
59. Cohen AD, Klunk WE.Early detection of Alzheimer's disease using PiB and FDG PET.Neurobiol Dis 2014; 72(Pt A): 117-22
60. Klunk WE, Engler H, Nordberg A, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.Ann Neurol 2004; 55(3): 306-19
61. Chien DT, Bahri S, Szardenings AK, et al.Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807.J Alzheimers Dis 2013; 34(2): 457-68
62. Fan Z, Aman Y, Ahmed I, et al.Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.Alzheimers Dement 2014.[Epub ahead of print
63. Kuhl DE, Koeppe RA, Minoshima S, et al.In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease.Neurology 1999; 52(4): 691-9
64. Kendziorra K, Wolf H, Meyer PM, et al.Decreased cerebral a4b2 nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.Eur J Nucl Med Mol Imaging 2011; 38(3): 515-25
65. Itoh M, Meguro K, Fujiwara T, et al.Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.Ann Nucl Med 1994; 8(4): 245-51
66. Kemppainen N, Ruottinen H, Na'gren K, Rinne JO.PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.Neurology 2000; 55(2): 205-9
67. Reeves S, Brown R, Howard R, Grasby P.Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.Neurology 2009; 72(6): 528-34
68. Ouchi Y, Yoshikawa E, Futatsubashi M, et al.Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease.J Nucl Med 2009; 50(8): 1260-6
69. Kepe V, Barrio JR, Huang SC, et al.Serotonin 1A receptors in the living brain of Alzheimer's disease patients.Proc Natl Acad Sci USA 2006; 103(3): 702-7
70. Truchot L, Costes SN, Zimmer L, et al.Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment.Neurology 2007; 69(10): 1012-17
71. Truchot L, Costes SN, Zimmer L, et al.A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease.Neuroimage 2008; 40(3): 1251-6
72. Sabri O, Tiepolt S, Hesse S, Barthel H.PET imaging of dementia.In: Hodler J, von Schulhess GK, Zollikofer L, editors.Diseases of the brain, head & neck, spine 2012-2015.Springer; 2012.p.244-50